- Home
- VCEL vs MIRM Comparison
VCEL vs MIRM Comparison
Compare VCEL & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCEL
- MIRM
- Stock Information
- Founded
- VCEL 1989
- MIRM 2018
- Country
- VCEL United States
- MIRM United States
- Employees
- VCEL N/A
- MIRM N/A
- Industry
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- VCEL Health Care
- MIRM Health Care
- Exchange
- VCEL Nasdaq
- MIRM Nasdaq
- Market Cap
- VCEL 2.1B
- MIRM 2.5B
- IPO Year
- VCEL 1997
- MIRM 2019
- Fundamental
- Price
- VCEL $40.15
- MIRM $50.30
- Analyst Decision
- VCEL Strong Buy
- MIRM Strong Buy
- Analyst Count
- VCEL 8
- MIRM 9
- Target Price
- VCEL $62.00
- MIRM $66.22
- AVG Volume (30 Days)
- VCEL 430.8K
- MIRM 468.1K
- Earning Date
- VCEL 07-31-2025
- MIRM 08-06-2025
- Dividend Yield
- VCEL N/A
- MIRM N/A
- EPS Growth
- VCEL 521.85
- MIRM N/A
- EPS
- VCEL 0.05
- MIRM N/A
- Revenue
- VCEL $238,541,000.00
- MIRM $379,251,000.00
- Revenue This Year
- VCEL $23.03
- MIRM $35.83
- Revenue Next Year
- VCEL $24.52
- MIRM $16.83
- P/E Ratio
- VCEL $705.61
- MIRM N/A
- Revenue Growth
- VCEL 14.80
- MIRM 69.31
- 52 Week Low
- VCEL $37.39
- MIRM $33.52
- 52 Week High
- VCEL $63.00
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- VCEL 44.33
- MIRM 59.09
- Support Level
- VCEL $40.53
- MIRM $47.89
- Resistance Level
- VCEL $43.57
- MIRM $51.93
- Average True Range (ATR)
- VCEL 1.62
- MIRM 1.49
- MACD
- VCEL -0.16
- MIRM -0.25
- Stochastic Oscillator
- VCEL 28.65
- MIRM 59.65
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.